On August 4, Merck rose 3.31% in pre-market trading, trading at $131.99/share. The movement was driven by the convergence of the company's quarterly earnings release before market open and a simultaneous analyst upgrade from Jefferies.

Merck reported its latest quarterly results ahead of the bell, with pre-market strength suggesting performance may have exceeded previously cautious market expectations. Multiple institutions had adopted conservative profit assumptions heading into the quarter, citing elevated R&D and commercialization spending, potential one-time items impacting EPS, and product mix shifts pressuring near-term net margins. On the same day, Jefferies raised its target price on Merck from $147 to $152, further boosting sentiment. This follows recent upgrades from Barclays (target to $150 from $140), JPMorgan ($140 from $135), and BMO ($142 from $135), reflecting broad institutional confidence in the company's pipeline trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)